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Background: The present study was designed to evaluate the clinical course and response to preventive cardiac resynchronization therapy with 
defibrillator (CRT-D) in patients with ischemic heart disease (IHD) and nonischemic heart disease (NIHD) enrolled in MADIT-CRT.
Methods: We evaluated the risk for the primary end point of death or heart failure event, whichever came first, in patients with IHD (n=1046) and 
NIHD (n=774) who were enrolled in the MADIT-CRT trial . The Cox model for CRT-D vs. ICD-only hazard ratio was used to evaluate treatment efficacy 
by disease etiology. The contribution of dichotomized risk variables to the treatment effect was investigated including risk factor-by-treatment 
interactions.
Results: Among patients allocated to ICD-only therapy, IHD was associated with a significant 62% (p=0.02) increase in the risk of the primary end 
point as compared with NIHD. However, CRT-D therapy was associated with a somewhat more favorable response in NIHD patients (Table). Females, 
patients with diabetes mellitus, and those with LBBB, derived enhanced efficacy from CRT-D therapy in the NIHD subgroup, with significant risk 
factor-by-treatment interaction, and LBBB was associated with enhanced efficacy in the IHD subgroup (Table).
Conclusions: Our findings demonstrate differences in clinical course and response to preventive CRT-D therapy between IHD and NIHD patients 
enrolled in MADIT-CRT, suggesting that risk assessment in the 2 subgroups should be carried out separately.
The Effect of CRTD Treatment by Etiology
Ischemic Nonischemic
Adjusted Hazard Ratio
(p value)
p value for interaction
Adjusted Hazard Ratio
(p value)
p value for interaction
CRTD Overall -
0.62
(<0.01)
-
0.53
(<0.01)
-
Gender Female
0.45
(0.06) 0.40
0.20
(<0.001) <0.01
Male
0.66
(<0.01)
0.86
(0.61)
Diabetes Yes
0.56
(<0.01) 0.50
0.23
(<0.01) 0.04
No
0.68
(0.04)
0.66
(0.14)
LBBB Yes
0.44
(<0.001) <0.01
0.35
(<0.001) <0.01
No
1.13
(0.61)
2.21
(0.22)
